Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents

Drugs

Volumn 60, Issue SUPPL. 1, 2000, Pages 25-32

  Ciardiello, F ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BROMOANILINO) 6 (METHYLAMINO)PYRIDO[3,4 D]PYRIMIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; AUTOCRINE EFFECT; CANCER CHEMOTHERAPY; CARCINOGENESIS; CONFERENCE PAPER; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; RECEPTOR UPREGULATION;

EID: 0033757346     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200060001-00003     Document Type: Conference Paper

References (44)

1. Epidermal growth factor-related peptides and their receptors in human malignancies
2. Anticancer drug targets: Growth factors and growth factor signaling
3. The epidermal growth factor receptor and its inhibition in cancer therapy
4. Therapeutic application of anti-growth factor receptor antibodies
5. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice
6. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody tO recombinant ricin A chain
7. Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction
8. Epidermal growth factor receptors in human breast carcinoma cells: A potential selective target for transforming growth factor α-Pseudomonas exotoxin 40 fusion protein
9. Targeted inhibition of tumor cell growth by a bispecific single-chain toxin containing an antibody domain and TGFα
10. Biological efficacy of a Chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model
11. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy
12. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
13. Inhibitors of tyrosine kinase
14. Tyrosine kinase inhibitors: 10. Isomeric 4-[(3-bromophenyl) amino] pyrido [d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor
15. Protein tyrosine kinase inhibitors as novel therapeutic agents
16. Tyrosine kinase inhibitors in preclinical development
17. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily
18. Tyrophostins. 6. Dimeric benzylidenemalononitrile tyrophostins: Potent inhibitors of EGF receptor tyrosine kinase in vitro
19. Phase I clinical trial of the flavinoid quercetin: Pharmacokinetics and evidence for in vivo tyrosine kinase inhibition
20. Genistein exerts multiple suppressive effects on human carcinoma cells
21. In vivo toxicity, pharmacokinetics and anticancer activity of genistein linked to recombinant human epidermal growth factor
22. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: Progression from reversible to irreversible inhibitors
23. 4,5-bis (4-fluoroanilino) phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity
24. Tyrosine kinase inhibitors: 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido [3,4-d] pyrimidine (PD 158780), a potent and specific inhibitor of the tyrosine kinase actitvity of receptors for the EGF family of growth factors
25. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma
26. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase
27. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner
28. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor
29. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase
30. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines
31. ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor selected for clinical development
32. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor
33. Antitumour activity of combined blockade of epidermal growth factor receptor and protein kinase A
34. Neutralizing antibodies against epidermal growth factor and erbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo
35. Antiepidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
36. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms
37. Potentiation of cytotoxic agents against human tumors in nude mice by ZD1839 (Iressa(TM)), an inhibitor of EGFR tyrosine kinase, does not require high levels of expression of EGFR
38. ZD1839 ('Iressa') as an anticancer agent
39. Epidermal growth factor receptor family and chemosensitization
40. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts
41. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies
42. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225